Open AccessThe Biology Behind mTOR Inhibition in Sarcoma
Author(s) -
Wan Xiaolin,
Helman Lee J.
Publication year - 2007
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1634/theoncologist.12-8-1007
Subject(s) - pi3k/akt/mtor pathway , medicine , tolerability , discovery and development of mtor inhibitors , clinical trial , everolimus , temsirolimus , cancer research , cancer , sirolimus , pharmacology , bioinformatics , oncology , signal transduction , biology , adverse effect , biochemistry
Learning Objectives After completing this course, the reader will be able to: Discuss the function of the mTOR pathway in cancer cell growth and survival. Describe the potential mechanism of targeting this pathway by rapamycin and its derivatives for cancer therapy. Summarize the clinical trials performed with mTOR inhibitors in the treatment of sarcomas and suggest the future clinical development of these inhibitors in the treatment of sarcomas.Access and take the CME test online and receive 1 AMA PRA Category 1 Credit ™ at CME.TheOncologist.com